11-Mar-2025 4:06 AM CST - Yahoo Finance 3 Reasons to Avoid VRTX and 1 Stock to Buy Instead Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%.
11-Mar-2025 3:25 AM CST - The Motley Fool Where Will Vertex Pharmaceuticals Be in 10 Years? The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.
5-Mar-2025 7:17 AM CST - Business Insider TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX) TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX - Research Report) today and set a price target of
18-Feb-2025 3:05 PM CST - Business Wire Vertex to Participate in Upcoming March Investor Conferences Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice Pres
11-Mar-2025 4:06 AM CST - Yahoo Finance 3 Reasons to Avoid VRTX and 1 Stock to Buy Instead Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%.
11-Mar-2025 3:25 AM CST - The Motley Fool Where Will Vertex Pharmaceuticals Be in 10 Years? The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.
5-Mar-2025 7:17 AM CST - Business Insider TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX) TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX - Research Report) today and set a price target of
18-Feb-2025 3:05 PM CST - Business Wire Vertex to Participate in Upcoming March Investor Conferences Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice Pres
